Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
Oncotarget|May 19, 2016
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking statusChia-Hung Hsu, Chien-Hua Tseng, Chun-Ju Chiang, et al.
JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.
Lancet (London, England)|June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialLuis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Therapeutic Advances in Medical Oncology|June 7, 2021
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 studyYen-Hsiang Huang, Jen-Yu Hung, How-Wen Ko, et al.
Oncotarget|December 13, 2017
EGFR mutation, smoking, and gender in advanced lung adenocarcinomaChien-Hua Tseng, Chun-Ju Chiang, Jeng-Sen Tseng, et al.
Plos One|March 20, 2015
Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in TaiwanKuo-Hsuan Hsu, Chao-Chi Ho, Te-Chun Hsia, et al.
Carcinogenesis|December 10, 2015
EGFR mutation and lobar location of lung adenocarcinomaChien-Hua Tseng, Kun-Chieh Chen, Kuo-Hsuan Hsu, et al.
American Journal of Respiratory and Critical Care Medicine|September 27, 2016
Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase InhibitorsI-Shou Chang, Shih Sheng Jiang, James Chih-Hsin Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutationsShinsheng Yuan, Sung-Liang Yu, Hsuan-Yu Chen, et al.
Med (New York, N.Y.)|October 10, 2024
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trialQing Zhou, Yan Yu, Ligang Xing, et al.
Pageof 18